title: [Retrospective analysis of elderly patients > or = 60 years of age with acute leukemia].
abstract: A retrospective analysis was performed on 76 consecutive elderly patients with acute leukemia aged 60 years or more (48 men, 28 women). Forty patients were 60-69 years old, 28 were 70-79 years old and 8 were > or = 80 years old. There were 55 patients with acute myelogenous leukemia (AML), 13 acute lymphoblastic leukemia (ALL) and 8 AML from myelodysplastic syndrome (MDS/AML). Patients were treated with the JALSG protocol, CAG regimen, or low-dose Ara-C regimen for AML, and DVP/M-CHOP protocol for ALL. The complete remission (CR) rates were 52.7% (29 of 55) in AML, 61.5% (8 of 13) in ALL, and 0% in MDS/AML. The median CR durations were 226, 85, 0 days, and the median survivals were 204, 177, 99 days, respectively. CR rates were 65.3% for the JALSG protocol, 62.5% for the CAG regimen and 25.0% for low-dose Ara-C regimen. According to age, CR was obtained 62.5% in patients aged 60-69 years and 33.3% in patients over 70 years old. Our results indicated that patients aged 60-69 years should be treated with intensive chemotherapy.
authors.affiliation: Department of Medicine, Jichi Medical School.
authors.forename: M
authors.initials: M
authors.lastname: Tabata
authors.forename: M
authors.initials: M
authors.lastname: Yoshida
authors.forename: T
authors.initials: T
authors.lastname: Izumi
authors.forename: C
authors.initials: C
authors.lastname: Kawano
authors.forename: R
authors.initials: R
authors.lastname: Kuribara
authors.forename: M
authors.initials: M
authors.lastname: Toshima
authors.forename: K
authors.initials: K
authors.lastname: Omine
authors.forename: M
authors.initials: M
authors.lastname: Takatoku
authors.forename: M
authors.initials: M
authors.lastname: Uchida
authors.forename: K
authors.initials: K
authors.lastname: Kirito
authors.forename: A
authors.initials: A
authors.lastname: Miyazato
authors.forename: H
authors.initials: H
authors.lastname: Takahashi
authors.forename: M
authors.initials: M
authors.lastname: Hoshino
authors.forename: Y
authors.initials: Y
authors.lastname: Terui
authors.forename: H
authors.initials: H
authors.lastname: Tomizuka
authors.forename: T
authors.initials: T
authors.lastname: Otsuki
authors.forename: R
authors.initials: R
authors.lastname: Shimizu
authors.forename: J
authors.initials: J
authors.lastname: Tsunoda
authors.forename: K
authors.initials: K
authors.lastname: Muroi
authors.forename: Y
authors.initials: Y
authors.lastname: Furukawa
authors.forename: Y
authors.initials: Y
authors.lastname: Amemiya
authors.forename: S
authors.initials: S
authors.lastname: Imagawa
authors.forename: N
authors.initials: N
authors.lastname: Komatsu
authors.forename: T
authors.initials: T
authors.lastname: Suzuki
authors.forename: Y
authors.initials: Y
authors.lastname: Miura
mesh_terms: D015250:Aclarubicin / Q000008:administration & dosage; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004247:DNA / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage; D012189:Retrospective Studies; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D014750:Vincristine; D015250:Aclarubicin; D003520:Cyclophosphamide; D004247:DNA; D011239:Prednisolone; D015122:Mercaptopurine; D008727:Methotrexate; D003630:Daunorubicin